Leerink Partners analyst Puneet Souda has maintained their bullish stance on BRKR stock, giving a Buy rating on April 11.
Puneet Souda has given his Buy rating due to a combination of factors including Bruker’s strategic positioning and financial metrics. The company is currently trading at a valuation that is considered attractive, with its EV/EBITDA multiple significantly lower than both its historical average and its industry peers. This suggests potential for upside as the company continues to grow and navigate economic uncertainties.
Additionally, Bruker’s recent product launches, such as the 1.3 Ghz UHF NMR, are expected to enhance margins and drive revenue growth. The company’s ability to install and book high-value NMR systems, particularly in the UK, further supports confidence in its growth prospects. These factors, combined with a steady growth expectation despite a challenging economic backdrop, underpin Souda’s positive outlook on Bruker’s stock.
In another report released on April 11, Bank of America Securities also reiterated a Buy rating on the stock with a $76.00 price target.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BRKR in relation to earlier this year.